Icotrokinra
Overview
Icotrokinra (brand: Icotyde) is a first-in-class oral macrocyclic peptide developed by Johnson & Johnson and Protagonist Therapeutics. It selectively blocks the interleukin-23 (IL-23) receptor, shutting down the IL-23/Th17 inflammatory pathway that drives autoimmune diseases. FDA approved March 17, 2026 for moderate-to-severe plaque psoriasis in patients 12 years and older weighing at least 40 kg. Unlike prior biologics (injected), this is taken orally, marking a breakthrough in peptide-based autoimmune therapy.
Protocols & dosing
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
Icotrokinra is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.
| Country | Status |
|---|---|
| United States | FDA approved |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
References
No external sources have been catalogued for this article yet.
Related peptides
- AMP-K — Metabolic immune support
- Beta-Glucan Peptide — Immune activating complex
- Groprinosin — Antiviral immune booster
- Imunofan — Russian immune peptide
- KPV — Anti-inflammatory immune peptide
- LL-37 — Antimicrobial defense peptide